Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
Colorcon
McKinsey
Mallinckrodt
Federal Trade Commission
Cipla
Fuji
Express Scripts

Generated: October 18, 2018

DrugPatentWatch Database Preview

Vemurafenib - Generic Drug Details

« Back to Dashboard

What are the generic sources for vemurafenib and what is the scope of vemurafenib freedom to operate?

Vemurafenib is the generic ingredient in one branded drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for vemurafenib
Synonyms for vemurafenib
[(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6 -dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone
1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-
1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-
1029872-54-5
207SMY3FQT
3og7
4CA-1032
918504-65-1
A25476
AB0031775
AB01273970_03
AB01273970-01
AB1009703
ABP000429
AC-25010
ACN-030372
AK-56796
AKOS007930804
AM81259
AN-1313
ANW-69692
AOB87705
AX8212389
BC626573
BDBM50396483
BRAF(V600E) Kinase Inhibitor RO5185426
BRD-K56343971-001-02-3
C23H18ClF2N3O3S
CHEBI:63637
CHEMBL1229517
CS-0216
CTK8C3113
D09996
D0Y9EW
DB08881
DTXSID50238710
EX-A053
EX-A1335
FT-0660388
FT-0675792
FT-0689782
GPXBXXGIAQBQNI-UHFFFAOYSA-N
GTPL5893
HE070213
HE290987
HE413595
HMS3265M03
HMS3265M04
HMS3265N03
HMS3265N04
HMS3654P09
HSDB 8143
HY-12057
IN2235
J-522975
J-690009
KB-59765
KS-0000002Q
MCULE-7244406627
ME-0096
MFCD18074504
MolPort-009-200-481
N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide
n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide
N-(3-([5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE
N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine
N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide
N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide
N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide
N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide
N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide
N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
NCGC00250399-01
NSC-761431
NSC761431
PB11741
PLX 4032
PLX-4032
PLX-4032(RG7204)/PLX4032
PLX4032
PLX4032 - Vemurafenib
PLX4032 ,Vemurafenib ,
PLX4032 (Vemurafenib)
PLX4032, RG7204, RO5185426, 1029872-54-5
PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf
propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
Q-3409
QCR-44
R-7204
RG 7204
RG-7204
RG7204
RL05788
Ro 51-85426
RO 5185426
RO-5185426
RO5185426
s1267
SC-54548
SCHEMBL298931
SR-01000941568
SR-01000941568-1
ST24048327
SYN1161
TC-158437
TRA0082406
UNII-207SMY3FQT
Vemurafenib (BRAF inhibitor)
Vemurafenib (JAN/USAN/INN)
Vemurafenib (PLX4032, RG7204)
Vemurafenib (PLX4032)
Vemurafenib [USAN:INN]
Vemurafenib, RG7204, RO5185426
Vemurafenib;PLX-4032
vemurafenibum
Y0473
Zelboraf
Zelboraf (TN)
ZINC52509366
ZX-AFC000306

US Patents and Regulatory Information for vemurafenib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for vemurafenib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90026-2 Sweden ➤ Try a Free Trial PRODUCT NAME: VEMURAFENIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/12/751/001 20120217
2012010,C1893612 Lithuania ➤ Try a Free Trial PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
2 5012-2012 Slovakia ➤ Try a Free Trial FIRST REGISTRATION NO/DATE: EU/1/12/751/001, 20120217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
Colorcon
McKinsey
Mallinckrodt
Federal Trade Commission
Cipla
Fuji
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.